Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3337-3344

  Ramalingam, Suresh S ^a   Blackhall, Fiona ^b   Krzakowski, Maciej ^d   Barrios, Carlos H ^e   Park, Keunchil ^f   Bover, Isabel ^h   Heo, Dae Seog ^g   Rosell, Rafael ⁱ   Talbot, Denis C ^c   Frank, Richard ^j   Letrent, Stephen P ^k   Ruiz Garcia, Ana ^k   Taylor, Ian ^k   Liang, Jane Q ^k   Campbell, Alicyn K ^k   O'Connell, Joseph ^k   Boyer, Michael ^l  

^a EMORY UNIVERSITY   (United States)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h HOSPITAL SON LLÀTZER   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j NORWALK HOSPITAL   (United States)

^k PFIZER INC   (United States)

^l SYDNEY CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; QUINAZOLINONES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866255620     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.9433     Document Type: Article

References (24)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
2. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092, 2005 (Pubitemid 46657411)
3. Bronte G, Rizzo S, La Paglia L, et al: Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 36:S21-S29, 2010 (suppl 3)
4. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
6. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005 (Pubitemid 40637826)
7. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001 (Pubitemid 33674041)
8. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932, 2007
9. Gonzales AJ, Hook KE, Althaus IW, et al: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible panerbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7:1880-1889, 2008
10. Jänne PA, Boss DS, Camidge DR, et al: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139, 2011
11. Janne P, Reckamp K, Koczywas M, et al: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol 27:422s, 2009 (suppl; abstr 8063)
12. Park K, Seog Heo D, Chul Cho B, et al: Updated safety and efficacy results of a phase 1/2 study of PF299804 in Korean patients with NSCLC who experienced disease progression on platinum-based chemotherapy plus gefitinib or erolotinib. J Thorac Oncol 5:S371-S423, 2010 (suppl; abstr O-018)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Ramalingam SS, Boyer MJ, Park K, et al: Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: Quantitative and qualitative benefits. Ann Oncol 21:viii, 122, 2010 (suppl 8; abstr 365PD)
15. Heo D, Kim J, Cho B: First report of PF00299804 in Asian patients: A Korean phase I/II study in KRAS wild-type, stage IIIb/IV non-small cell lung cancer, refractory to chemotherapy and erlotinib or gefitinib. Presented at the World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009 (suppl; abstr)
16. Barraclough H, Simms L, Govindan R: Biostatistics primer: What a clinician ought to know - Hazard ratios. J Thorac Oncol 6:978-982, 2011
17. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
18. Roberts PJ, Stinchcombe TE, Der CJ, et al: Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28:4769-4777, 2010
19. Shepherd FA: Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost? J Clin Oncol 29:4068-4070, 2011
20. Hartmann JT, Haap M, Kopp HG, et al: Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481, 2009
21. Li T, Perez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107-119, 2009
22. Ouwerkerk J, Boers-Doets C: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 14:337-349, 2010
23. Peppercorn JM, Smith TJ, Helft PR, et al: American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol 20; 29:755-760, 2011
24. Klüter S, Simard JR, Rode HB, et al: Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: A tool for dissecting kinase drug resistance. Chembiochem 11:2557-2566, 2010